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The mammalian ortholog of the retroviral oncogene v-Eyk, and a receptor tyrosine kinase upstream of
antiapoptotic and transforming signals, Mer (MerTK) is a mediator of the phagocytic process, being
involved in retinal and immune cell clearance and platelet aggregation. Mer knockout mice are viable
and are protected from epinephrine-induced pulmonary thromboembolism and ferric chloride-induced
thrombosis. Mer overexpression, on the other hand, is associated with numerous carcinomas. Although
Mer adaptor proteins and signaling pathways have been identiﬁed, it remains unclear how Mer initiates
phagocytosis. When bound to its nucleotide cofactor, the high-resolution structure of Mer shows an auto-
inhibited aC-Glu-out conformation with insertion of an activation loop residue into the active site. Mer
complexed with compound-52 (C52: 2-(2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine),
a ligand identiﬁed from a focused library, retains its DFG-Asp-in and aC-Glu-out conformation, but
acquires other conformational changes. The aC helix and DFGL region is closer to the hinge region and
the ethanolamine moiety of C52 binds in the groove formed between Leu593 and Val601 of the P-loop,
causing a compression of the active site pocket. These conformational states reveal the mechanisms of
autoinhibition, the pathophysiological basis of disease-causing mutations, and a platform for the devel-
opment of chemical probes.
 2008 Elsevier Inc. Open access under CC BY license.1. Introduction
Mer is a transmembrane tyrosine receptor kinase with extracel-
lular immunoglobulin and ﬁbronectin-like domains that recognize
ligands such as growth arrest speciﬁc 6 (Gas6) and protein S (Haﬁzi
andDahlback, 2006a). Ligand-binding leads to autophosphorylation
of activation loop tyrosine (Tyr749, Tyr753 and Tyr754) (Ling et al.,
1996), recruitment of adaptor proteins (Grb2, LimD4, and Vav1)
(Colland et al., 2004; Georgescu et al., 1999; Ling and Kung, 1995;
Mahajan and Earp, 2003), and activation of downstream enzymes
(PI3K, MAPK, and GTPase) (Chen et al., 1997; Ling and Kung, 1995).
Mer behaves as a proto-oncogene, having roles in cellular transfor-
mation of NIH/3T3 and B-lymphocytes cells (Georgescu et al.,
1999; Ling and Kung, 1995). Its expression and activity is elevatedstitute, University of Toronto,
M5G 1L5. Fax: +1 416 946
. Dhe-Paganon).
Y license.in various human cancers including pituitary adenomas (Evans
et al., 2001),mantle cell lymphomas (Ek et al., 2002), andT-cell acute
lymphoblastic leukemia (Graham et al., 2006). Transgenic mice that
overexpress Mer in lymphocytes and thymocytes developed lym-
phoblastic leukemia/lymphoma (Keating et al., 2006). Mice lacking
either Gas6 or Mer have impaired platelet aggregation in vitro and
decreased stability of clots in vivo (Angelillo-Scherrer et al., 2001;
Chenet al., 2004). AndMermediatesphagocyticprocesses thatoccur
in monocytes, macrophages, and retinal pigment epithelial cells.
Mutations in theMerTK genehave been shown to disrupt retinal pig-
ment epithelial phagocytosis in rats and mice (D’Cruz et al., 2000;
Duncan et al., 2003), and result in retinitis pigmentosa in patients
(Gal et al., 2000). Mer-deﬁcient mice also exhibited impaired clear-
ance of apoptotic thymocytes (Scott et al., 2001). Although each
member of the Mer subfamily, including Axl and Sky, functions in
regulating cell proliferation and platelet aggregation, it appears that
only Mer is involved in provoking phagocytosis. Given the role of
Mer in the pathophysiology of thrombosis and tumorigenesis,
including acute lymphoblastic leukemia, inhibition of Mer may be
an option for therapeutic intervention of these diseases.
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tumorigenesis, including acute lymphoblastic leukemia, inhibition
of Mer may be an option for therapeutic intervention in these dis-
eases. A soluble form of Mer that acts as an antagonist decreased
platelet aggregation in vitro and prevented fatal collagen/epineph-
rine-induced thromboembolism in mice (Sather et al., 2007). And
Mer or Gas6 knockout mice were protected from collagen/epineph-
rine-induced pulmonary thromboembolism and ferric chloride-in-
duced thrombosis (Angelillo-Scherrer et al., 2001; Chen et al.,
2004). So far, no speciﬁc small molecule inhibitors for Mer have
been reported. Recent successes in the treatment of chronic mye-
logenous leukemia with Imatinib, a small molecule that targets
the constitutively active tyrosine kinase BCR-ABL (Druker et al.,
1996; Savage and Antman, 2002), has encouraged us to study the
biochemical properties of Mer and search for chemical probes de-
spite the challenges posed by major overall similarity in the ATP
binding sites of protein kinases.
In contrast to the amino-terminal lobes, the helical carboxyl-
terminal lobe of protein kinases is considerably more conserved
in terms of both primary and tertiary sequence. While the car-
boxy-terminal lobe evolved to contain important determinant for
substrate binding, the amino-terminal lobe of protein kinases con-
tain many determinants that control the reaction cycle. The amino-
terminal lobe is composed of a twisted ﬁve-stranded b-sheet with
a closely associated alpha-helix (aC) running the length of one side
of the b-barrel-like substructure. The pocket formed between the
carboxy- and amino-terminal lobes is the site of binding of ATP
as well as many small molecule inhibitors or probes. We have be-
gun to investigate the structural characteristics of the Mer kinase
domain and its active site with structures of various ligands. The
amino-terminal lobe adopts an orientation with the DFG-Asp in
the ‘‘in” position and the aC-Glu in the ‘‘out” position. We charac-
terized determinants of Mer inhibition by screening small mole-
cule inhibitors and elucidated the structural interaction between
an inhibitor and the Mer kinase domain. Our studies represent
the ﬁrst solved structure of the intracellular kinase domain of a
member of the Axl/Mer/Sky RTK phylogenetic branch, provide in-
sight into the mechanism of inhibition of Mer tyrosine kinase
activity, and set a platform for future studies of Mer sequence vari-
ants in retinitis pigmentosa.
2. Materials and methods
2.1. RTK expression and puriﬁcation
The Mer kinase domain (residues 588–855) and the catalytic
domain of human protein tyrosine phosphatase PTPN1 (1–283 res-
idues) were cloned together as a bicistron into a bacterial
expression vector pET28-LIC. The kinase ORF #1 contained an
N-terminal His tag and thrombin cleavage site. The untagged
phosphatase was ORF #2. The intergenic sequence contained a
ribosomal binding site (CTCGACGGAGGAATAATCAT). Plasmids
were transformed into BL21(DE3) cells, grown in TB media at
37 C using an aeration system (LEX), and induced at 15 C with
100 lM IPTG. Cell pellets were harvested after overnight bubbling
at 15 C and stored at 80 C.
The Mer protein was puriﬁed in two chromatographic steps:
immobilized metal afﬁnity chromatography on a Talon resin (Qia-
gen) and gel ﬁltration. Cell pellets from 4 L culture were homoge-
nized in 100 ml lysis buffer containing 50 mM Tris–HCl pH 8.0,
500 mM NaCl, 5% glycerol, 1 mM b-mercaptoethanol, 2 mM imid-
azole, and lysed using a microﬂuidizer at 18,000 psi (Microﬂui-
dics). The lysed cells were centrifuged at 69,000g for 1 h. The
supernatant was incubated with 5.0 ml 50% Talon resin for 1 h at
4 C, and then washed two times with 25 ml washing buffer
(50 mM Tris–HCl pH 8.0, 500 mM NaCl, 5% glycerol, 1 mMb-mercaptoethanol, 10 mM imidazole). The protein was eluted
with 7 ml elution buffer (50 mM Tris–HCl pH 8.0, 500 mM NaCl,
5% glycerol, 1 mM b-mercaptoethanol, 200 mM imidazole). The
eluent was further puriﬁed by the gel ﬁltration AKTAxpress system
on a 16/65 Superdex 200 column (GE Healthcare) pre-equilibrated
with the gel ﬁltration buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 5%
glycerol, 2 mM b-mercaptoethanol). The yield of 7.3 mg/L of bacte-
rial culture; puriﬁed protein was frozen in liquid nitrogen and
stored at 80 C. Autophosphorylation of Mer was performed at
room temperature for 3 h with 10 mM ATP (Sigma, A7699) and
10 mM MgCl2 in gel ﬁltration buffer (20 mM Tris, pH 8.0,
500 mM NaCl, 5% glycerol, and 2 mM b-mercaptoethanol).
2.2. Positional scanning peptide screens
Mer phosphorylation speciﬁcity was determined by screening a
library of 198 peptide mixtures. Each peptide had the general se-
quence G-A-X-X-X-X-X-Y-X-X-X-X-A-G-K-K(biotin), in which 8 of
the 9 positions indicated as X were equimolar mixtures of the 18
amino acids, excluding tyrosine and cysteine. The remaining X po-
sition was ﬁxed as one of the 20 amino acids or as phosphothreo-
nine or phosphotyrosine. Peptides (50 lM) were incubated in
sealed multiwell plates for 2 h at 30 C with phosphorylated Mer
(80 ng/ml) in 50 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM DTT, 0.1%
Tween-20, with 50 lM [33P]-c-ATP (0.03 lCi/ll). Aliquots of the
reactions were then spotted onto a streptavidin coated membrane,
which was washed, dried and exposed to a phosphor screen as de-
scribed (Turk et al., 2006).
2.3. Kinase Inhibitor library screening
A library of kinase inhibitors was screened using differential
scanning ﬂuorimetry with a FluoDia T70 (PTI) according to the out-
lined protocol (Niesen et al., 2007). The library consisted of 157
compounds at 50 lM concentration in 100 mM Hepes pH 7.5,
150 mM NaCl.
2.4. Docking simulations
Flexible compounds were initially docked in a rigid grid repre-
sentation of the receptor with Glide XP (Schrodinger LLC). In the
case of staurosporine and compound-52, minor side-chain rear-
rangements were necessary to accommodate the ligand, and ICM
(Molsoft LLC) was used to minimize in the internal coordinate
space by a Monte Carlo simulation the energy of a system com-
prised of the ﬂexible and mobile ligand and ﬂexible receptor
side-chains within 7 Å of the active site (Totrov and Abagyan,
1997).
2.5. Protein kinase assays
Kinase activity assays, including those used for kinetics mea-
surements, were performed using the ADP Quest Assay (Discov-
eRx) and following the protocol for kinetic mode provided by the
manufacturer. Kinase activity was monitored using a BioTek Syn-
ergy 2 plate reader operating in kinetic mode and ﬂuorescence
intensity measurements (540 nm excitation and 620 nm emission)
were made once per minute. Mer proteins used in the kinetic as-
says were present at 25 nM concentration, the ATP concentration
ranged from 10 to 200 lM, and the peptide concentration ranged
from 0.1 to 2 mM. Fluorescence intensity values were converted
to moles of ADP using a standard curve prepared as described in
the ADP Quest Assay manual and the correlation between ADP con-
centration and ﬂuorescence intensity was linear over the range of
values obtained in these experiments. Dual-substrate experiments
that were used to calculate kinetic parameters were performed in
Table 1
Data collection, phasing, and reﬁnement statistics.
Dataset ADP ANP C52
PDB code 3BRB 2P0C 3BPR
Space group P21 P21 P21
Unit cell 53.38 89.88 69.54
90.00 103.09 90.00
52.47 90.06 69.25
90.00 102.44 90.00
70.00 91.70 120.74
90.00 94.06 90.00
Beamline CHESS F-1 FR-E APS 17ID
Wavelength 0.918 1.54178 1
Resolution 25.00–1.90 25.00–2.40 50.00–2.80
Unique reﬂections 49802 24544 37537
Data redundancy 7.5 (5.2) 3.5 (3.4) 3.3 (2.9)
Completeness** 98.3 (88.7) 99.8 (99.7) 99.0 (94.3)
I/sigI 24.1 (2.4) 21.6 (5.2) 9.1 (2.3)
Rsym
*** 0.09 (0.66) 0.06 (0.29) 0.15 (0.53)
Reﬁnement
Resolution 25–1.9 24.8–2.4 47.3–2.8
Reﬂections used 47038 23326 35338
All atoms {non-
protein atoms}
4502 {303} 4186 {233} 8428 {134}
Rwork/Rfree**** 0.19/0.24 0.20/0.27 0.27/0.30
Rmsd bond length 0.013 0.009 0.011
Rmsd bond angle 1.511 1.201 1.242
Figure of merit 0.77 0.82 0.67
Mean B factor 34 39.1 58.4
Ramachandran plot
Favoured 97.9 97.2 95.3
Allowed 2.1 2.8 4.7
Disallowed 0 0 0
Atomic coordinates were deposited in the Protein Data Bank (www.rcsb.org).
** Highest-resolution shell is shown in parentheses.
*** Rsym = 100  sum(|I  hIi|)/sum(hIi), where I is the observed intensity and hIi is
the average intensity from multiple observations of symmetry-related reﬂections.
**** Rfree value was calculated with 5% of the data.
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regression with data from 5 to 11 min of the reaction, a time over
which the reaction generally produced linear data. The background
reaction rate, resulting from ADP contamination of the ATP stock
solution, was measured in a reaction lacking enzyme or substrate
and subtracted from the experimental rates. Kinetics parameters
were obtained by ﬁtting the rates using the two-substrate format
in the Enzyme Kinetics module of SigmaPlot v9.01 and the data
were best ﬁt with a Random Bi–Bi Sequential model. The time-re-
sponse comparison of Mer (543.864) was performed in the same
manner as the kinetics experiments except that only a single con-
centration of ATP (250 lM) and peptide (2 mM) were employed.
Mer proteins were used at 25 nM. IC50 experiments were per-
formed using the ADP Quest Assay in kinetics mode. All com-
pounds assayed in the experiments were determined to be
compatible with the assay in separate experiments (data not
shown). ATP-treated Mer was at 25 nM, ATP was 250 lM, and
the peptide substrate was at 2 mM. Depending on the experiment,
either four or ﬁve different concentrations of each inhibitor were
tested and each set of experiments were performed in duplicate.
2.6. Crystallization, data collection, phasing, and reﬁnement
All crystals were grown at 14 C using the hanging-drop va-
por-diffusion method. Mer-ANP complex crystals were grown
by mixing 2 ll Mer solution (35 mg/ml Mer (571–864), 2.5 mM
ANP, 10 mM MgCl2) and 2 ll reservoir solution (100 mM Tris–
HCl pH 8.5, 200 mM MgCl2, 29% PEG 400). Mer-ADP crystals
were obtained by pre-incubating 38 mg/ml Mer protein with
2.5 mM ATP and 10 mM MgCl2 for 3 h at room temperature
and grown by mixing 2 ll with 2 ll reservoir solution as above.
Compound-52 (50 mM in DMSO) was added to 8 mg/ml Mer
protein to the ﬁnal concentration of 2.5 mM, rocked at 4 C over-
night, and further concentrated to about 35 mg/ml. Crystals were
grown by mixing 2 ll Mer and 2 ll reservoir solution (100 mM
Tris–HCl pH 8.5, 3.64 M NaCl). Crystals were frozen in a cryopro-
tectant composed of 9% sucrose (wt/vol), 2% glucose (wt/vol), 8%
glycerol (vol/vol), and 8% ethylene glycol (vol/vol) in reservoir
buffer. Data for the ANP co-crystal structure was collected on a
Rigaku FR-E equipped with a RAXIS-4++ detector. The data were
processed with HKL-2000 (Minor et al., 2002; Otwinowski and
Minor, 1997), and then input into the program PHASER (Read,
2001) using the pdb entry 2G15 as the molecular replacement
search model. Iterative manual model building using the graph-
ics program O (Jones et al., 1991), density modiﬁcation and auto-
matic model building using RESOLVE (Terwilliger, 2000), and TLS
and restrained reﬁnement using Refmac 5.2 (1994) resulted in a
model with a working R value of 0.20 and a free R value of 0.27
for the resolution range from 2.4 to 24.8 Å. Two molecules of the
MerTK catalytic domain are present in the asymmetric unit. Res-
idues 552–574, 596–597, 622–632, 658–664, 745–762, and 862–
864 in chain A, as well as residues 552–574, 596–598, 622–632,
658–664, 745–762, 862–864 in chain B were not located in the
experiment.
Data for the compound-52 co-crystal structure was collected
at the Argonne Photon Source IMCA-CAT beamline 17ID, and
processed using HKL-2000. Chain A from the ANP co-crystal
structure was used as the molecular replacement model for this
structure. Manual building of the model was carried out using
the graphics program Coot (Emsley and Cowtan, 2004) and
TLS and restrained reﬁnement using Refmac 5.2 resulted in a
model with a working R value of 0.27 and a R free of 0.30
for data from 47.3 to 2.8 Å. Four molecules of the Mer catalytic
domain are present in the asymmetric unit. Tight NCS restraints
were used in the reﬁnement of this structure. Residues from
chain A 552–574, 623–666, 746–762, 864; chain B 552–574,596, 625–630, 660–666, 746–762, 864; chain C 552–574, 623–
630, 660, 663–666, 746–762, 864; and chain D 552–574, 623–
630, 662–666, 746–762 and 864 were not located in the
experiment.
Data for the ADP co-crystal structure was collected at the F-1
beamline at the Cornell High Energy Synchrotron Source, and
processed using HKL-2000. Chain A from the AMP-PNP co-crystal
structure was used as the molecular replacement model for this
structure. Autobuilding of the structure and location of water
molecules was carried out using the program ARP/wARP (Perra-
kis et al., 1999), followed by iterative manual model building
using the graphics program Coot, and TLS and restrained reﬁne-
ment using Refmac 5.2. For each of the three structures the ini-
tial TLS parameters were generated using the TLSMD web server
(Painter and Merritt, 2006). Two molecules of the MerTK cata-
lytic domain are present in the asymmetric unit. Residues from
chain A 552–574, 596, 622–624, 659–665, 746–761, 864; and
chain B 552–574, 745–762, and 864 were not located in the
experiment. Further details of data collection and reﬁnement
can be found in the Table 1.
3. Results and discussion
3.1. Overall structures
To characterize the active site and regulatory mechanisms of
Mer and advance rational approaches toward the development of
chemical probes, crystal structures of its kinase domain with
nucleotide ligands ADP and ANP and the inhibitor compound-52
(C52) were determined (Table 1). These structures had good elec-
tron density for most residues and revealed the canonical protein
kinase fold: b-stranded amino-terminal and a-helical carboxy-ter-
minal lobes. The ADP and ANP nucleotide structures superimposed
K619 K619
D741 D741
L744 L744
E637 E637
N728 N728
ADP ADP
F742 F742
G743 G743
R727 R727
C C
4 4
5 5
2 21 1
E E
D D
A
K619 K619
D741 D741
N728 N728
1 1
5 5
D D
C52 C52
B
D678 D678
Fig. 1. Active site structure and complex with compound-52. (A) A close-up, stereoscopic view of the active site of Mer (ADP bound) is shown in Pymol cartoon format,
colored light brown. ADP is colored cyan and shown in stick format. The DGF loop and aC-Glu are also shown in stick format and labeled. Water molecules within 6 Å of the
nucleotide and catalytic residues are shown as red stars, and the magnesium ion as a green sphere. Hydrogen bonds with distances less than 3.2 Å are shown as black, dashed
lines. (B) Stereoscopic view of the ligand-binding pocket of Mer. A carved, surface representation of the pocket formed upon compound-52 binding is shown colored
transparent-gray. Surrounding, catalytic side-chains are shown in stick format; waters and hydrogen bonds to the ligand are shown as above.
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DFG-Asp motif is in the ‘‘in” position, with Phe742 buried in its
canonical pocket, forming van der Waals contacts with residues
in the aC helix, aC-b4 loop, b6-strand, and aE helix (Fig. 1A). The
DFG-Asp741 is poised in a catalytically competent state; its car-
boxyl group is involved in hydrogen bonds with (1) a chelated
magnesium ion and its coordinated water molecules, (2) the amino
group of the catalytic lysine (Lys619), and (3) the amide group of
the catalytic Asn728. In addition, the carboxyl group is hydrogen
bonded to a water molecule that is trapped in the core of the active
site, between but not hydrogen-bonded to the DFG-Phe742,
Ala740, Leu671, and the nucleotide. The magnesium ion is coordi-
nated to the a- and b-phosphoryl oxygens, two axial water mole-
cules, the Asn728 side-chain, and the DFG-Asp741 carboxyl
group, consistent with a typical protein kinase catalytically compe-
tent state. However, aC-Glu (Glu637), which is a critical residue for
catalytic turnover, is in the aC-Glu-out conformation (Fig. 1A).
Although mostly solvent-exposed, one oxygen atom of its carboxyl
group hydrogen-bonds with the backbone amide of Leu744, the
ﬁrst and only residue of the activation loop that is ordered in our
structures. The side-chain of Leu744 is buried in the interlobepocket, above DFG-Phe742 and between the aC helix and the
b4- and b5-strands; it is also protected from the solvent by the
side-chain of the aC-Glu637. This residue is conserved among
Mer paralogs and its aliphatic nature is conserved among all recep-
tor tyrosine kinases; the analogous residues of EGFR paralogs have
been implicated in regulatory transitions, stabilizing the inhibited,
aC-Glu-out conformation; mutagenesis of this residue to arginine
leads to activation of EFGR1 (Zhang et al., 2006). Mer was superim-
posed with other DFG-Asp-in/aC-Glu-out structures, including
those from Abl, Src, Egfr, Chk, and Met kinases, showing that the
orientations of aC helices relative to the rest of the b-lobe domain
were similar. Also conserved in these inhibited states is an ali-
phatic residue immediately following DFG that inserts into the
space generated by the outward movement of the aC helix. The
aC-Glu-out conformation represents one of the most familiar
inhibited tyrosine kinase states, and it likely evolved as an efﬁcient
way to minimize inappropriate activation of the receptor under ba-
sal, unstimulated conditions.
Mer contains a number of tyrosine residues in the juxtamem-
brane and C-terminal tail that in addition to being adaptor protein
binding sites (Georgescu et al., 1999) could also regulate catalytic
92 X. Huang et al. / Journal of Structural Biology 165 (2009) 88–96efﬁciency. To attempt to characterize how upstream signals induce
activation of the Mer kinase enzyme, we conducted biochemical
analyses, focusing on the role of the juxtamembrane segment
(JMS) because this region of the protein contains a rare variant
(E540K) associated with retinal disease (Tada et al., 2006). In order
to explore the possibility that Mer is autoregulated by an autophos-
phorylation event of its juxtamembrane region (which contains a
single tyrosine (Tyr549)), we ﬁrst showed by mass-spectrometry
(infusion electrospray MS and LCMS/MS) that the Mer JMS tyrosine
(Tyr549) is a potential autophosphorylation site. The phosphatase-
coexpressed kinase, which was devoid of phosphorylation sites,
could be modiﬁed by treatment with ATP, and supports the possi-
bility of a post-translational regulatory event (Supplementary
Fig. 1). To test if unphosphorylated Tyr549 is inhibitory, in amanner
analogous to the JMS tyrosine residues of Eph receptors (Davis et al.,
2008; Wiesner et al., 2006; Wybenga-Groot et al., 2001), we
followed the reaction using dephosphorylated forms of the JMS-
containing kinase constructs (Binns et al., 2000). For these studies,
a 9 residue peptide substrate was developed using a positionalR844
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peptide: ADEPNYETWG. The enzyme had robust catalytic activity
with this substrate, initially suggesting that the inhibited, crystal-
line state is not a dominant or stable species in solution.When com-
pared to unphosphorylated wild-type kinase, the ATP-pretreated
wild-type kinase had similar initial rates (data not shown), sugges-
tion either that the JMS is not involved in regulation or that phos-
phorylation of the JMS is faster than our assay setup, a scenario
reminiscent of the Eph kinase system (Binns et al., 2000). To trap
potential inhibitory species, we mutated the single juxtamembrane
segment tyrosine (Tyr549) to phenylalanine. We found that instead
of inhibiting the enzyme, as might be suspected in a scenario such
as the Eph kinase (Wybenga-Groot et al., 2001), we found that this
mutation caused mild activation of the enzyme. At saturating ATPR844
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Staurosporine 51.2 ± 0.1 0.03 ± 0.002
Cdk1 Inhibitor, CGP74514A 48.1 ± 0.1 3.3 ± 0.1
5-Iodotubercidin 46.8 ± 0.2 6.3 ± 0.4
BIM 9; Bisindolylmaleimide IX 44.6 ± 0.1 5.3 ± 0.8
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Fig. 3. Kinase library screen and validation. (A) Average and standard deviation of
the melting temperature of untreated Mer kinase domain, as determined by
differential scanning ﬂuorimetry, in the presence of compounds, and sorted by
value. The Tm of the protein without ligand is highlighted (40.5 C). (B) Six
compounds that induced the highest shifts in the Tm of Mer are shown, along with
the Tm of Mer in the presence of each compound as well as IC50 values measured for
each compound according to the methods section. Tm values are an average of two
measurements made on the same plate. (C) Correlation plot between IC50 values
and delta-Tm. (D) Chemical structures and names of inhibitors of Mer.
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tion of the optimized peptidewith a kcat/Km of 0.0010 ± 0.0001 M1 s
1 and the Y549F mutant with a kcat/Km of 0.0051 ± 0.0002 M1 s1.
That the mutation potentiated the enzyme suggests that the juxta-
membrane segment is not likely to have an autoinhibitory role anal-
ogous to Eph kinases. It remains possible that the juxtamembrane is
involved in a phosphorylation-independent, autoactivation mecha-
nism analogous to that of EGFR (Jeffrey et al., 1995; Zhang et al.,
2006). Although size-exclusion chromatography did not provide evi-
dence for JMS-dependant dimerization (data not shown), the Mer
JMS could accelerate autoactivation through transient homophilic
interactions in a manner consistent with ligand-dependant receptor
dimerization and activation (Haﬁzi and Dahlback, 2006a,b; Haﬁzi
et al., 2002; Taylor et al., 1995). The function of juxtamembrane
Tyr549 and its possible phosphorylation remains unknown.
3.2. Mutations in retinitis pigmentosa
Mutation screening of the MERTK gene in retinal dystrophy pa-
tients has identiﬁed a number of disease-associated changes,
including point mutations and small rearrangements predicting
premature protein truncation and splicing defects (Ebermann
et al., 2007; Gal et al., 2000; McHenry et al., 2004; Tada et al.,
2006; Tschernutter et al., 2006). Several missense variants were
also identiﬁed, representing both frequent and rare polymor-
phisms, some of which are located in the Mer intracellular region:
E540K, S661C, R844C, R865W, I871T, and R909H (Fig. 2, left). To
date, there is clear evidence (genetic and/or biochemical) for dis-
ease-association of only one Mer missense change: R844C. The
Cys844 variant segregated with retinitis pigmentosa in the affected
family, and the corresponding recombinant protein exhibited de-
creased expression and tyrosine kinase activity, and increased pro-
tein turnover (McHenry et al., 2004). Arg844 projects its
guanidinium group into the core of the C-terminal lobe, forming
a buried salt bridge with the carboxyl group of Glu770 and hydro-
gen-bonding with backbone atoms of Lys780 and Arg838 (Fig. 2B).
As part of the ‘‘APE” aEF helix, Glu770 represents an anchor point
for the activation loop, as it is intimately associated with proper
substrate binding through the P + 1 and aEF-aF loops, helping to
shape the platform on which substrates and activation loop folds
(Nolen et al., 2004). This E:R ion pair is conserved among many ki-
nases, and its mutation to cysteine could lead to protein destabili-
zation, consistent with increased protein turnover in vitro and
associated pathophysiology in vivo.
Although other rare Mer coding variants have been detected
only in retinal dystrophy patients, their effect on function has
not yet been established. The rare variant S661C is also located
in the Mer kinase domain. However, our structure shows that
Ser661 is completely solvent exposed in the b4–b5 loop (Fig. 2A),
and interestingly it is one of six residues in the b4–b5 loop unique
to this phylogenetic branch (Supplementary Fig. 3), the role of
which is unknown. Thus, it appears that the S661C substitution
would not radically affect function, consistent with it being a rare
variant with unknown disease-association. Nevertheless, its loca-
tion in a unique insertion sequence may point to a role in catalysis.
Taken together, our Mer structure will be useful for predicting
whether amino acid differences corresponding to human coding
variants in the intracellular domain are likely to perturb critical
functional interactions, and for planning future studies to evaluate
involvement in the pathogenesis of retinitis pigmentosa.
3.3. Kinase inhibitors
Because Mer is associated with tumorigenesis and thrombosis,
chemical probes that target Mer functions may be scientiﬁcally
and therapeutically useful. To generate a preliminary ligand-spec-iﬁcity map of the active site, a 157-compound kinase inhibitor li-
brary (Supplementary Fig. 4) was screened using differential
scanning ﬂuorimetry (Niesen et al., 2007; Senisterra et al., 2006).
ATP-pre-treated Mer at 10 lMwas pre-incubated with compounds
94 X. Huang et al. / Journal of Structural Biology 165 (2009) 88–96at 50 lM and subjected to thermal denaturation. Six compounds
stabilized Mer with a value greater than 4 C compared with the
average aggregation temperature of 38.5 ± 0.2 C (Fig. 3A and D).D
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strate, to obtain IC50 values with a correlation with delta-Tm
(Fig. 3B and C). Ligand hits can be subdivided into two general scaf-
fold classes: (1) purine derivatives and (2) staurosporine and other
pyrrolinone or maleimide-based compounds (Fig. 3D, top and bot-
tom, respectively).
To determine the mode of binding of these compounds, inhib-
itors were co-crystallized, and a complex structure was deter-
mined with C52, a ligand developed from combinatorial
synthesis of 2,6,9-trisubstituted purines (Gray et al., 1998). Re-
lated compounds purvalanol B and roscovitine were studied pre-
viously in complex with Src and Cdk2 (Breitenlechner et al., 2005;
De Azevedo et al., 1997; Gray et al., 1998). C52 bound co-planar
with ATP of the Mer–ATP complex, occupying the adenine and su-
gar pockets (Fig. 1B) and having good shape-complimentarity to
this region of the pocket; its isoproply group ﬁlls the space
formed between Ala617, Lys619, Met730, Asp741, and Leu671
and its ethanolamine moiety binds in the groove formed between
Leu593 and Val601. The hydroxyl group of C52 hydrogen-bonds
to the carboxylate of Asp678 and the carbonyl oxygen of
Arg727. Compared with the nucleotide-bound complex, the N-
terminal lobe of the C52 complex is rotated (about 5) relative
to and is more closely associated with the C-terminal, helical
lobe. For example, the distance between the tertiary carbon atom
of Val601 and the sulfur atom of Met730 is 1.0 Å less in the C52
complex structure. In addition, hydrogen bonds are present be-
tween (1) the purine N7 nitrogen and the backbone nitrogen of
Met674, (2) the ligand’s aniline nitrogen and the carbonyl of
Met674, and (3) the ligand and the carboxylic group of Asp678;
one via a water molecule. Complementary, van der Waals interac-
tions also form between the chloro-phenyl ring of C52 and back-
bone atoms of the hinge region (residues 674–676). Retaining its
DFG-Asp-in and aC-Glu-out conformation, C52 draws the entire
N-lobe, including aC, towards the hinge region (674–676), caus-
ing relocation of the aliphatic DFGL-Leu744.
In order to better understand the speciﬁcity of the pocket, the
remaining ligand hits were docked to the ATP site of our high-res-
olution Mer crystal structure bound to ATP with Glide (Schroding-
er) and ICM (Molsoft LLC). The pyrrolinone group of staurosporine
and SU9516, and maleimide group of BIM-9 make a canonical dual
hydrogen bond with the backbone nitrogen of M674 and carbonyl
of P672; the docked conformations are in agreement with co-crys-
tal structures of staurosporine, SU9516 and BIM-9 bound to other
kinases (2CLQ, 1PF8, 2V7O, respectively) (Fig. 4). The docked con-
formation of C52 recapitulates our co-crystal structure, but the
hydroxyethanolamine tail hydrogen-bonds to the carboxylate
group of Asp741 instead of Asp678. The close analog CDK1 inhibi-
tor is posed in a very similar way. And, 5-iodotubercidine mimics
the binding of adenosine in our ATP co-crystal, with the additional
iodide deeply buried in a hydrophobic cavity composed of Leu671,
Met730, and the aliphatic moiety of Lys619. As a potential site for
the development of inhibitor speciﬁcity, the N9 isopropyl group of
C52 points towards Ile650, which is one of the few positions of the
nucleotide binding pocket that is divergent among the Axl mem-
bers (Axl, Mer, and Sky). Although C52 and analogs studied here
may not be therapeutically useful because of their potential non-
speciﬁcity and toxicity, the present structures provide the ﬁrst
view of the Mer kinase domain and will be useful for computa-
tional chemistry approaches towards inhibitor discovery and
optimization.
High-resolution, complex structures of the Mer kinase domain
were determined, showing autoinhibited aC-Glu-out conforma-
tions. These structures are the ﬁrst to be determined from the
Mer/Axl/Sky subfamily of receptor tyrosine kinases, and provide
a detailed map of the interactions made by residues implicated
in retinitis pigmentosa. As this protein is a proto-oncogene and isoverexpressed in a large number of tumors, ligands, or chemical
probes may help show a potential therapeutic window for Mer ki-
nase inhibition. The inhibited conformation of the N-lobe could be
targeted for the discovery and development of anticancer drugs.
We identiﬁed a preliminary series of ligands that may help address
these challenges.
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